Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharm
Multiple Sclerosis Therapeutics Market, By Drug Class (Beta Interferon, Corticosteroids, Monoclonal Antibodies, Antineoplastic Agent, Others), By Route of Administration (Oral, Injection, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
Multiple sclerosis (MS) is a chronic autoimmune disorder that affects the central nervous system (CNS). It is caused when the immune system attacks myelin, the protective sheath surrounding nerve fibers of the CNS. The damage disrupts communication between the brain and other parts of the body. Symptoms can be mild or severe, depending on the number and location of lesions in the CNS. Common symptoms include fatigue, weakness or numbness in the limbs, poor coordination and balance, vision problems, and cognitive dysfunction. There has been no known cure for MS but medications such as interferons, glatiramer acetate, monoclonal antibodies, corticosteroids can manage the disease symptoms and slow down its progression.
Market Dynamics:
Global multiple sclerosis therapeutics market growth is driven by factors like increasing prevalence of multiple sclerosis across both developed and developing nations, growing geriatric population, robust pipeline of new and innovative treatment therapies for multiple sclerosis, surging healthcare spending, and availability of reimbursement schemes. However, high costs associated with multiple sclerosis drugs can hamper the market growth. Emergence of personalized medicines for multiple sclerosis treatment, growing adoption of combination therapies, infusion therapies, and oral drugs for multiple sclerosis treatment can offer market growth opportunities.
Key features of the study:
This report provides in-depth analysis of the global multiple sclerosis therapeutics market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global multiple sclerosis therapeutics market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Biogen, Novartis, Merck, Sanofi, Teva Pharmaceuticals, Bayer, ACORDA THERAPEUTICS and CELGENE
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global multiple sclerosis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global multiple sclerosis therapeutics market
Detailed Segmentation-
By Drug Class Insights (Revenue, USD Bn, 2019 - 2031)
Beta Interferon
Corticosteroids
Monoclonal Antibodies
Antineoplastic Agent
Others
By Route of Administration Insights (Revenue, USD Bn, 2019 - 2031)
Oral
Injection
Others
By Distribution Channel Insights (Revenue, USD Bn, 2019 - 2031)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
By Regional Insights (Revenue, USD Bn, 2019 - 2031)
North America
U.S.
Canada
Latin America
Brazil
Argentina
Mexico
Rest of Latin America
Europe
Germany
U.K.
Spain
France
Italy
Russia
Rest of Europe
Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
Middle East
GCC Countries
Israel
Rest of Middle East
Africa
South Africa
North Africa
Central Africa
Key Players Insights
Biogen Inc.
Novartis AG
Merck KGaA
Sanofi S. A.
Acorda Therapeutics, Inc.
Teva Pharmaceuticals Industries Ltd.
Bristol-Myers Squibb Company
Bayer AG
Hoffmann-La Roche AG
Viatris Inc. (Mylan NV)
Johnson & Johnson
EMD Serono, Inc.
TG Therapeutics, Inc.
Genentech, Inc.
Celgene Corporation
AbbVie Inc.
Amgen Inc.
UCB S.A.
Sandoz (a Novartis division)
Ipsen S.A.
1. Research Objectives and Assumptions
Research Objectives
Assumptions
Abbreviations
2. Market Purview
Report Description
Market Definition and Scope
Executive Summary
Global Multiple Sclerosis Therapeutics Market, By Drug Class
Global Multiple Sclerosis Therapeutics Market, By Route of Administration
Global Multiple Sclerosis Therapeutics Market, By Distribution Channel
Global Multiple Sclerosis Therapeutics Market, By Region
3. Market Dynamics, Regulations, and Trends Analysis
Market Dynamics
Impact Analysis
Key Highlights
Regulatory Scenario
Product Launches/Approvals
PEST Analysis
PORTER’s Analysis
Merger and Acquisition Scenario
4. Global Multiple Sclerosis Therapeutics Market, By Drug Class, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
Beta Interferon
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Corticosteroids
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Monoclonal Antibodies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Antineoplastic Agent
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
5. Global Multiple Sclerosis Therapeutics Market, By Route of Administration, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020- 2031
Segment Trends
Oral
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Injection
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
6. Global Multiple Sclerosis Therapeutics Market, By Distribution Channel, 2019-2031, (USD Bn)
Introduction
Market Share Analysis, 2024 and 2031 (%)
Y-o-Y Growth Analysis, 2020 - 2031
Segment Trends
Hospital Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Retail Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
Online Pharmacies
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
7. Global Multiple Sclerosis Therapeutics Market, By Region, 2019 - 2031, (USD Bn)